Search

Agent-based modelling (ABM) is a facet of wider Multi-Agent Systems (MAS) research that explores the collective behaviour of individual 'agents', and the implications that their behaviour and interactions have for wider systemic behaviour. The method has been shown to hold considerable value in exploring and understanding human societies, but is still largely confined to use in academia. This is particularly evident in the field of Urban Analytics; one that is characterised by the use of new forms of data in combination with computational approaches to gain insight into urban processes. In Urban Analytics, ABM is gaining popularity as a valuable method for understanding the low-level interactions that ultimately drive cities, but as yet is rarely used by stakeholders (planners, governments, etc.) to address real policy problems. This paper presents the state-of-the-art in the application of ABM at the interface of MAS and Urban Analytics by a group of ABM researchers who are affiliated with the Urban Analytics programme of the Alan Turing Institute in London (UK). It addresses issues around modelling behaviour, the use of new forms of data, the calibration of models under high uncertainty, real-time modelling, the use of AI techniques, large-scale models, and the implications for modelling policy. The discussion also contextualises current research in wider debates around Data Science, Artificial Intelligence, and MAS more broadly. [ABSTRACT FROM AUTHOR]

Skin cancers are the most common cancers in the UK. Malignant Melanoma (MM) is the most dangerous type of skin cancer. Primary Care Physicians (GPs) often have difficulty in distinguishing harmless skin blemishes from MM, leading to many patients being referred to dermatology departments. There have been enormous advances recently in the application of computer‐based Artificial Intelligence (AI) to the field of image analysis. This paper from four authors in London (UK) explores the current position of AI systems in analysing skin lesions (affected patches of skin). Important AI concepts such as convolutional neural networks (CNN) and "deep learning" are explained. By exposing AI systems to hundreds of thousands of pictures of skin lesions, it is possible to "train" them to recognise lesions with a high degree of accuracy. Skin cancer detection, particularly melanoma detection, has now been tested by numerous different groups with multiple AI systems; the most successful ones are generally "convolutional neural networks". When comparing their performance to dermatologists who are presented with photographs of skin lesions, these AI systems perform similarly, if not better, at identifying whether something is a melanoma or a benign (non‐cancerous) mole. However, these programmes are limited by the data sets on which they have been "trained"; for example, a lot of the datasets are trained on Caucasian skin, and will perform less well when detecting melanoma in skin of colour, as they may not have been exposed to enough of this type of image to perform well. They have also not been shown to be particularly useful for diagnosing other types of skin conditions yet and they are not able to provide any kind of explanation for their classification. Because of these limitations, it is unlikely that they will replace dermatologists. The legal framework for AI systems also doesn't allow them to take responsibility for decisions, so responsibility for diagnosis still falls to a responsible clinician. However, in the near future they may well prove to be extremely useful in aiding GPs in making clinical decisions about skin lesions, particularly with regards to urgent referrals to dermatology. Linked Article: Du-Harpur et al. Br J Dermatol 2020; 183:423–430. Linked Article: Du-Harpur et al. Br J Dermatol 2020; 183:423–430. [ABSTRACT FROM AUTHOR]